Stockscreener 앱 받기
14.32
1.15%
-0.14
전일 마감가:
$14.46
열려 있는:
$14.34
하루 거래량:
437.72K
Relative Volume:
0.28
시가총액:
$1.39B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-30.47
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
+1.08%
1개월 성능:
+11.67%
6개월 성능:
-6.70%
1년 성능:
+46.60%
1일 변동 폭
$14.03
$14.35
1주일 범위
$13.45
$15.05
52주 변동 폭
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
14.33 | 1.39B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.20 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.98 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals Partners with ALK for Neffy Promotion - Investing.com Australia
ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US - marketscreener.com
ARS Pharma in pact with ALK-Abelló to co-promote neffy - Seeking Alpha
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S - marketscreener.com
ALK-Abello (AKBLF) Partners with ARS Pharma for Needle-Free Alle - GuruFocus
ALK enters into neffy® co-promotion agreement in the USA - The Manila Times
ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season - Nasdaq
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ... - Eagle-Tribune
ARS Pharma Partners With ALK to Expand neffy Nasal Spray to 9,000 US Pediatricians | SPRY Stock News - Stock Titan
REG-ALK enters into neffy® co-promotion agreement in the USA - TradingView
ARS Pharmaceuticals Has A Blockbuster Candidate (NASDAQ:SPRY) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
(SPRY) On The My Stocks Page - news.stocktradersdaily.com
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia
US High Growth Tech Stocks To Watch Now - Yahoo Finance
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
10 Unstoppable Stocks That Could Double Your Money - Insider Monkey
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Raymond James maintains Strong Buy on SPRY stock, $32 target - Investing.com
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
neffy From ARS Pharmaceuticals, Inc - Pharmacy Times
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN
Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus
ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha
Raymond James maintains $28 target on ARS Pharma stock - Investing.com India
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):